English

ARTIMPLANT INTERIM REPORT JANUARY – JUNE 2011

Report this content

First six months

  • Net revenue amounted to SEK 9.7 million (9.8).*
  • The net loss totaled SEK 9.0 million (9.8).  
  • Earnings per stock unit amounted to SEK -0.08 (-0.16).
  • The result was affected by one-off items amounting to -0.9 million (-).
  • Artimplant's own sales as a proportion of total sales continued to increase and accounted for 72% (57) of product sales.
  • The Company has revised its cash flow target and the aim now is that a positive cash flow before changes in working capital will be achieved on a monthly basis during the first quarter of 2012 (previously the target was by the end of 2011).

Second quarter

  • Net revenue amounted to SEK 4.3 million (5.1).*
  • The net loss totaled SEK 5.2 million (5.0).  
  • Earnings per stock unit amounted to SEK -0.04 (-0.08).
  • The result was affected by one-off items amounting to -0.9 million (-).

Events after the period-end

  • Decision has been taken by the Company to open its own sales office in theUSA.

N. B. This is a translation from Swedish. The Swedish version shall always take precedence.

Artimplant will not hold a telephone conference by reason of this report. For further information see www.artimplant.com.

* Figures in brackets refer to the corresponding period last year


For additional information, please contact:
Kjell Thörnbring, CEO, phone +46 (0)31-746 56 54, +46 (0)703 11 90 25,
kjell.thornbring @artimplant.com

Further information at www.artimplant.com where one also can subscribe to future press releases; www.artimplant.com/investors-media/subscribe-to-press-releases.html


Artimplant
Artimplant’s mission is to restore the health of patients by offering medical professionals degradable implants that help the body to heal.

Artimplant is a medical technology company that restores health through the development, production and marketing of degradable implants that regenerate body functions and improve quality of life. Our products are made from Artelon®, a biomaterial developed by the Company. Artimplant produces implants for the treatment of osteoarthritis in hands and feet, shoulder and other soft tissue injuries as well as oral and veterinary applications. The Company's products are sold through licensees and own sales under Artimplant’s brand take place through agents and distributors.

Artimplant is a public company listed on the NASDAQ OMX Stockholm in the Small Cap segment and in the healthcare sector.

Forward-looking statements
This press release contains forward-looking statements as defined in theU.S.Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.

This is information which Artimplant shall make public pursuant to the Swedish Financial Instruments Act and the Swedish Securities Exchange and Clearing Operations Act and/or stock market agreements. Information was made available for publication on August 3, 2011 at 9:00 AM (CET).

Tags:

Interim report artimplant

Documents & Links